Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 185
interventional 155
Observational 29
Registry 1

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 111
Drug|Other 11
Procedure 6
Drug|placebo 5
Other 4
Biological 3
Device 3
Drug|Procedure 3
Biological|Other 2
Drug|Other|placebo 2
Biological|Drug 1
Biological|Drug|Other 1
Biological|Procedure 1
Dietary Supplement 1
Drug|Other|Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 51
Korea, Republic of 14
China 8
France 8
NA 8
Japan 6
Germany 4
Netherlands 2
Sweden 2
Taiwan 2
United States|France|Italy 2
Australia|Belgium|China|Germany|Japan|Singapore|Spain 1
Australia|Denmark|France|Germany|Spain|United Kingdom 1
Australia|Finland|France|Netherlands|Norway|Singapore|Slovakia|Spain|Sweden|United Kingdom 1
Austria 1
Austria|Bosnia and Herzegovina|Bulgaria|Croatia|Czech Republic|Lithuania|Romania|Serbia|Slovakia|Slovenia 1
Austria|Germany 1
Belgium|Czechia|France|Germany|Hungary|United Kingdom 1
Belgium|Denmark|France|Netherlands|United Kingdom 1
Belgium|France|Germany|Netherlands|United Kingdom 1
Brazil 1
Canada 1
Denmark|Finland|Germany|Norway|Sweden 1
Finland 1
Finland|France|Germany|Italy|Spain 1
Finland|France|Germany|Switzerland 1
France|Italy|Spain 1
Germany|Italy 1
India 1
Israel 1
Italy 1
Italy|Finland|France|Germany|Spain 1
Norway 1
Poland 1
Saudi Arabia 1
Spain 1
Spain|United States|Australia|Austria|Belgium|Canada|China|Czechia|France|Germany|Hungary|Italy|Korea, Republic of|Netherlands|Poland|Singapore|Sweden|United Kingdom 1
Switzerland 1
Taiwan|Thailand|Algeria|Egypt|India|Jordan|Lebanon|Russian Federation|Saudi Arabia|South Africa|Tunisia|Turkey 1
Turkey 1
United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Colombia|France|Germany|Hong Kong|Korea, Republic of|Mexico|Philippines|Singapore|Spain|Taiwan|United Kingdom 1
United States|Argentina|Australia|Belgium|Canada|Chile|Czechia|France|Germany|Hungary|Israel|Italy|Korea, Republic of|Netherlands|Norway|Poland|Singapore|Spain|Sweden|Taiwan|United Kingdom 1
United States|Argentina|Austria|Brazil|Bulgaria|Canada|China|Colombia|Czech Republic|Denmark|Egypt|France|Germany|Hong Kong|Hungary|Israel|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Norway|Poland|Romania|Russian Federation|Singapore|Slovakia|South Africa|Spain|Sweden|Taiwan|Thailand|Turkey|United Kingdom|Venezuela 1
United States|Australia|Austria|Canada|Czech Republic|France|Germany|Italy|Korea, Republic of|Netherlands|Poland|Spain|Switzerland 1
United States|Australia|Belgium|Canada|Finland|France|Germany|Italy|Netherlands|Poland|Singapore|Spain|United Kingdom 1
United States|Australia|Belgium|Canada|France|Italy|Netherlands|Singapore|Spain|Switzerland|United Kingdom 1
United States|Australia|Finland 1
United States|Austria|Belgium|Canada|China|Finland|France|Germany|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Singapore|Spain|United Kingdom 1
United States|Austria|Canada|Germany|Italy|Netherlands|Spain|United Kingdom 1
United States|Belgium|Canada|France|Japan|Netherlands|Spain|United Kingdom 1
United States|Belgium|France|Germany 1
United States|Belgium|France|Germany|Italy|Korea, Republic of|Netherlands|Poland|Spain|United Kingdom 1
United States|Belgium|France|Germany|Italy|Netherlands|Spain|United Kingdom 1
United States|Canada 1
United States|Czechia|France 1
United States|France|Germany|Italy 1
United States|France|Italy|Netherlands 1
United States|Japan 1

Sites per Study

Site_count Study_Count
1 74
2 7
3 4
4 10
5 6
6 3
7 3
8 5
9 4
10 1
11 5
13 2
15 1
16 5
17 2
18 1
19 2
20 1
21 1
25 1
26 1
28 1
29 1
35 1
36 2
37 1
50 1
57 1
61 1
106 1
113 1
114 1
116 1
165 1
651 1
938 1

Phase

Phase Study_Count
Phase 2 79
Phase 1 26
Phase 3 19
Phase 1/Phase 2 13
N/A 11
Phase 4 6
Phase 2/Phase 3 1

Number of Arms

Number_of_Arms Count_of_Studies
1 87
2 41
3 7
4 1
6 1
11 1
NA 17

Enrollment Metrics by Phase

Measure N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 2.0000 3.00 9.00000 2.00000 48 25.0000 28.00000
1st Qu. 36.0000 29.00 31.00000 25.00000 48 125.0000 31.75000
Median 57.0000 43.00 52.00000 39.00000 48 248.0000 44.00000
Mean 177.9091 70.92 56.18182 65.55844 48 313.2105 45.16667
3rd Qu. 183.5000 66.00 82.50000 63.00000 48 451.0000 58.50000
Max. 900.0000 320.00 120.00000 818.00000 48 908.0000 64.00000

Trial Group Type

group_type Group_Count
Experimental 163
Active Comparator 19
Other 18
NA 17
Placebo Comparator 7
No Intervention 4

Intervention Model

intervention_model Study_Count
Single Group Assignment 98
Parallel Assignment 34
Crossover Assignment 10
NA 10
Sequential Assignment 3

Primary Purpose

primary_purpose Study_Count
Treatment 141
Diagnostic 6
Supportive Care 5
Prevention 2
Other 1

Observational Studies

Studies by Country

Country Study_Count
United States 8
China 3
NA 3
Taiwan 3
France 2
Korea, Republic of 2
Belgium 1
Canada 1
Chile 1
Germany 1
Japan 1
Netherlands 1
Norway 1
Singapore 1

Sites per Study

Site_count Study_Count
1 24
5 3
47 1
75 1

Enrollment Metrics

Measure Observational
Min 1.0000
1st Qu 29.7500
Median 99.5000
Mean 289.3929
3rd Qu 300.0000
Max 1800.0000

Observation Model

observational_model Study_Count
Case-Only 12
Cohort 12
Case-Control 2
NA 2
Other 1

Time Perspective

time_perspective Study_Count
Prospective 20
Retrospective 7
Other 1
NA 1

Registries

Studies by Country

Country Study_Count
Argentina|Brazil|Costa Rica|France|Italy|Mexico|Peru|Spain 1

Sites per Study

Site_count Study_Count
9 1

Enrollment Metrics

Measure Registries
Min 5000
1st Qu 5000
Median 5000
Mean 5000
3rd Qu 5000
Max 5000

Registry Model

observational_model Study_Count
Case-Only 1

Time Perspective

time_perspective Study_Count
Other 1

Follow-up

target_duration Study_Count
30 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT01524848 Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib https://ClinicalTrials.gov/show/NCT01524848 Completed Scandinavian Sarcoma Group 2015-01-31
NCT03353753 Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies https://ClinicalTrials.gov/show/NCT03353753 Active, not recruiting Deciphera Pharmaceuticals LLC 2019-05-31
NCT03291054 Epacadostat and Pembrolizumab in Patients With GIST https://ClinicalTrials.gov/show/NCT03291054 Active, not recruiting Columbia University 2021-12-31
NCT03238820 Robotic Resection for Patients With Gastric Gastrointestinal Stromal Tumors: a Single-center Study https://ClinicalTrials.gov/show/NCT03238820 Completed Jinling Hospital, China 2016-08-05
NCT03171389 POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST https://ClinicalTrials.gov/show/NCT03171389 Recruiting Universität Duisburg-Essen 2018-09-22
NCT03165721 A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer https://ClinicalTrials.gov/show/NCT03165721 Completed National Institutes of Health Clinical Center (CC) 2020-02-24
NCT03158103 A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) https://ClinicalTrials.gov/show/NCT03158103 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-04-30
NCT03139487 A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism https://ClinicalTrials.gov/show/NCT03139487 Recruiting Asan Medical Center 2021-09-30
NCT02931929 MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT https://ClinicalTrials.gov/show/NCT02931929 Completed Medical University Innsbruck 2019-04-09
NCT02924714 SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST https://ClinicalTrials.gov/show/NCT02924714 Recruiting Oslo University Hospital 2022-11-30
NCT02889328 Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs https://ClinicalTrials.gov/show/NCT02889328 Completed Asan Medical Center 2017-08-09
NCT02884154 Feasibility and Yield of a New 20 G ProCore Needle With Coiled Sheath in the Gastrointestinal Subepithelial Tumors https://ClinicalTrials.gov/show/NCT02884154 Completed Pusan National University Hospital 2017-02-28
NCT02880020 Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT02880020 Recruiting Jonsson Comprehensive Cancer Center 2020-09-30
NCT02800330 The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib https://ClinicalTrials.gov/show/NCT02800330 Completed Erasmus Medical Center 2018-02-28
NCT02686944 A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors https://ClinicalTrials.gov/show/NCT02686944 Completed Immunicum AB 2019-05-10
NCT02638766 Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST https://ClinicalTrials.gov/show/NCT02638766 Recruiting Grupo Espanol de Investigacion en Sarcomas 2023-12-31
NCT02607332 Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib https://ClinicalTrials.gov/show/NCT02607332 Completed Asan Medical Center 2018-01-31
NCT02606097 Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation https://ClinicalTrials.gov/show/NCT02606097 Completed Chang Gung Memorial Hospital 2018-05-31
NCT04276415 DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST) https://ClinicalTrials.gov/show/NCT04276415 Recruiting Daiichi Sankyo, Inc. 2024-05-31
NCT02574663 TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT02574663 Completed TG Therapeutics, Inc. 2018-08-31
NCT02571036 A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies https://ClinicalTrials.gov/show/NCT02571036 Recruiting Deciphera Pharmaceuticals LLC 2021-02-28
NCT02508532 (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT02508532 Active, not recruiting Blueprint Medicines Corporation 2020-12-31
NCT02500797 Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT02500797 Active, not recruiting National Cancer Institute (NCI) 2019-04-01
NCT02365441 A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) https://ClinicalTrials.gov/show/NCT02365441 Recruiting Australasian Gastro-Intestinal Trials Group 2019-12-31
NCT02260505 Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) https://ClinicalTrials.gov/show/NCT02260505 Recruiting Centre Leon Berard 2022-12-31
NCT02257541 BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) https://ClinicalTrials.gov/show/NCT02257541 Completed Memorial Sloan Kettering Cancer Center 2019-03-25
NCT02216578 Ph II CABOGIST in GIST https://ClinicalTrials.gov/show/NCT02216578 Active, not recruiting European Organisation for Research and Treatment of Cancer - EORTC 2019-05-20
NCT02164240 Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST https://ClinicalTrials.gov/show/NCT02164240 Active, not recruiting Dana-Farber Cancer Institute 2016-12-31
NCT02103322 Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions https://ClinicalTrials.gov/show/NCT02103322 Completed Amneal Pharmaceuticals, LLC 2014-03-31
NCT02071862 Study of the Glutaminase Inhibitor CB-839 in Solid Tumors https://ClinicalTrials.gov/show/NCT02071862 Completed Calithera Biosciences, Inc 2019-03-31
NCT01294202 A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST https://ClinicalTrials.gov/show/NCT01294202 Completed Astex Pharmaceuticals, Inc. 2013-04-30
NCT01289028 Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib. https://ClinicalTrials.gov/show/NCT01289028 Completed Novartis 2014-07-31
NCT01275222 Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors https://ClinicalTrials.gov/show/NCT01275222 Completed Novartis 2008-09-30
NCT01271712 Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST) https://ClinicalTrials.gov/show/NCT01271712 Completed Bayer 2012-01-26
NCT01270984 Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects https://ClinicalTrials.gov/show/NCT01270984 Completed Chong Kun Dang Pharmaceutical 2010-12-31
NCT04282980 A Study of DCC-2618 (Ripretinib) Evaluating Efficacy, Safety, and Pharmacokinetics In Patients With Advanced Gastrointestinal Stromal Tumors (GIST) https://ClinicalTrials.gov/show/NCT04282980 Recruiting Zai Lab (Shanghai) Co., Ltd. 2021-06-30
NCT02015065 Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors https://ClinicalTrials.gov/show/NCT02015065 Completed National Institutes of Health Clinical Center (CC) 2016-05-04
NCT01991379 MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) https://ClinicalTrials.gov/show/NCT01991379 Recruiting Memorial Sloan Kettering Cancer Center 2021-11-30
NCT01907607 Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib https://ClinicalTrials.gov/show/NCT01907607 Completed Institut Bergonié 2016-12-31
NCT01874665 A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor https://ClinicalTrials.gov/show/NCT01874665 Completed Takeda 2015-02-28
NCT01863745 Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment https://ClinicalTrials.gov/show/NCT01863745 Active, not recruiting Novartis 2023-10-04
NCT01774162 EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration https://ClinicalTrials.gov/show/NCT01774162 Completed University of Alberta 2012-06-30
NCT01769248 Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle https://ClinicalTrials.gov/show/NCT01769248 Completed Northwestern University 2014-02-28
NCT01751919 A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I) https://ClinicalTrials.gov/show/NCT01751919 Completed Dong-A ST Co., Ltd. 2012-08-31
NCT01738139 Ipilimumab and Imatinib Mesylate in Advanced Cancer https://ClinicalTrials.gov/show/NCT01738139 Recruiting M.D. Anderson Cancer Center 2022-02-28
NCT01735968 A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients https://ClinicalTrials.gov/show/NCT01735968 Completed Novartis 2018-10-19
NCT01694277 Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib https://ClinicalTrials.gov/show/NCT01694277 Active, not recruiting AB Science 2020-06-30
NCT01643278 Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic https://ClinicalTrials.gov/show/NCT01643278 Completed National Cancer Institute (NCI) 2016-06-30
NCT01541709 Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI https://ClinicalTrials.gov/show/NCT01541709 Active, not recruiting Asan Medical Center 2020-12-31
NCT01506336 Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib https://ClinicalTrials.gov/show/NCT01506336 Completed AB Science 2011-09-30
NCT01483014 Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST) https://ClinicalTrials.gov/show/NCT01483014 Completed Novartis 2012-01-31
NCT01478373 Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib https://ClinicalTrials.gov/show/NCT01478373 Completed Novartis 2014-07-31
NCT01468688 A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients https://ClinicalTrials.gov/show/NCT01468688 Completed Novartis 2016-07-29
NCT01462994 Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST) https://ClinicalTrials.gov/show/NCT01462994 Completed Technische Universität München 2015-12-31
NCT01440959 Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258 https://ClinicalTrials.gov/show/NCT01440959 Completed Asan Medical Center 2013-03-31
NCT01421680 The Effects of Preoperative and Postoperative Oral Nutritional Supplements in Malnourished Post-gastrectomy Patients https://ClinicalTrials.gov/show/NCT01421680 Completed Seoul National University Hospital 2013-12-31
NCT01404650 Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor https://ClinicalTrials.gov/show/NCT01404650 Completed SCRI Development Innovations, LLC 2015-02-28
NCT01402089 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients https://ClinicalTrials.gov/show/NCT01402089 Completed Cantonal Hospital of St. Gallen 2015-07-31
NCT01396148 A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor https://ClinicalTrials.gov/show/NCT01396148 Completed Pfizer 2017-08-31
NCT01323400 Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) https://ClinicalTrials.gov/show/NCT01323400 Completed Centre Leon Berard 2014-04-30
NCT04344847 Incidental Finding of Gastrointestinal Stromal Tumors (GISTs) During Laparoscopic Sleeve Gastrectomy, How to Deal? How Much Safety Margin https://ClinicalTrials.gov/show/NCT04344847 Recruiting Zagazig University 2020-05-13
NCT04258956 A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy https://ClinicalTrials.gov/show/NCT04258956 Recruiting Maria Sklodowska-Curie Institute - Oncology Center 2021-04-30
NCT04254939 A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor https://ClinicalTrials.gov/show/NCT04254939 Recruiting CStone Pharmaceuticals 2020-12-30
NCT04193553 Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure https://ClinicalTrials.gov/show/NCT04193553 Recruiting Centre Leon Berard 2022-03-31
NCT04138381 Selinexor in Combination With Imatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors. https://ClinicalTrials.gov/show/NCT04138381 Recruiting Grupo Espanol de Investigacion en Sarcomas 2022-04-16
NCT04106024 Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial https://ClinicalTrials.gov/show/NCT04106024 Recruiting Cttq 2019-10-30
NCT04000529 Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies https://ClinicalTrials.gov/show/NCT04000529 Recruiting Novartis 2022-03-22
NCT03673501 A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib https://ClinicalTrials.gov/show/NCT03673501 Recruiting Deciphera Pharmaceuticals LLC 2021-06-30
NCT03609424 PDR001 Plus Imatinib for Metastatic or Unresectable GIST https://ClinicalTrials.gov/show/NCT03609424 Recruiting Asan Medical Center 2020-08-30
NCT03594422 A Study of HQP1351 in Patients With GIST or Other Solid Tumors https://ClinicalTrials.gov/show/NCT03594422 Recruiting Ascentage Pharma Group Inc. 2020-10-30
NCT03556384 Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) https://ClinicalTrials.gov/show/NCT03556384 Recruiting University of California, San Diego 2021-09-30
NCT03471273 Comparison of Endoscopic and Laparoscopic Resection for Small Gastric Gastrointestinal Stromal Tumor https://ClinicalTrials.gov/show/NCT03471273 Recruiting Nanfang Hospital of Southern Medical University 2021-10-30
NCT03465722 (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST https://ClinicalTrials.gov/show/NCT03465722 Active, not recruiting Blueprint Medicines Corporation 2021-04-30
NCT03440515 Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor https://ClinicalTrials.gov/show/NCT03440515 Completed Asan Medical Center 2017-06-30
NCT03426722 L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors https://ClinicalTrials.gov/show/NCT03426722 Recruiting Asan Medical Center 2020-03-31
NCT01267695 Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor https://ClinicalTrials.gov/show/NCT01267695 Completed Peking University 2014-10-31
NCT01265810 Caphosol in Oral Mucositis Due to Targeted Therapy https://ClinicalTrials.gov/show/NCT01265810 Completed Impaqtt Foundation 2015-08-31
NCT01243346 Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene https://ClinicalTrials.gov/show/NCT01243346 Completed Arog Pharmaceuticals, Inc. 2014-07-31
NCT01154452 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma https://ClinicalTrials.gov/show/NCT01154452 Completed National Cancer Institute (NCI) 2015-02-28
NCT01151852 Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT https://ClinicalTrials.gov/show/NCT01151852 Completed Asan Medical Center 2013-03-31
NCT01114087 Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility https://ClinicalTrials.gov/show/NCT01114087 Completed Assistance Publique - Hôpitaux de Paris 2009-05-31
NCT01091207 Sorafenib for Imatinib/Sunitinib-failed GIST https://ClinicalTrials.gov/show/NCT01091207 Completed Samsung Medical Center 2010-12-31
NCT01068769 Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor https://ClinicalTrials.gov/show/NCT01068769 Active, not recruiting Dana-Farber Cancer Institute 2012-06-30
NCT00998751 Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST) https://ClinicalTrials.gov/show/NCT00998751 Completed AB Science 2013-06-30
NCT00940563 A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors https://ClinicalTrials.gov/show/NCT00940563 Completed Novartis 2004-08-31
NCT00867113 Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) https://ClinicalTrials.gov/show/NCT00867113 Completed Novartis 2016-12-20
NCT03944304 Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. https://ClinicalTrials.gov/show/NCT03944304 Recruiting Asan Medical Center 2020-08-01
NCT02401815 PLX9486 as a Single Agent and in Combination With PLX3397 or PLX9486 With Sunitinib in Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT02401815 Active, not recruiting Plexxikon 2020-05-31
NCT01110668 Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST) https://ClinicalTrials.gov/show/NCT01110668 Completed Novartis 2011-09-30
NCT01560260 Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors https://ClinicalTrials.gov/show/NCT01560260 Completed National Cancer Institute (NCI) 2015-10-31
NCT02834013 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors https://ClinicalTrials.gov/show/NCT02834013 Recruiting National Cancer Institute (NCI) 2021-08-31
NCT01172548 Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST) https://ClinicalTrials.gov/show/NCT01172548 Completed Novartis 2014-03-31
NCT00793871 Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor https://ClinicalTrials.gov/show/NCT00793871 Completed Pfizer 2014-04-30
NCT00785785 A Study of Nilotinib Versus Imatinib in GIST Patients https://ClinicalTrials.gov/show/NCT00785785 Completed Novartis 2014-10-31
NCT00780494 Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma https://ClinicalTrials.gov/show/NCT00780494 Completed Stanford University 2017-12-31
NCT00769782 Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor https://ClinicalTrials.gov/show/NCT00769782 Completed Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan 2016-03-31
NCT00764595 Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor https://ClinicalTrials.gov/show/NCT00764595 Completed Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan 2016-03-31
NCT00756509 Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib https://ClinicalTrials.gov/show/NCT00756509 Active, not recruiting Novartis 2022-12-31
NCT00718562 Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib https://ClinicalTrials.gov/show/NCT00718562 Completed Novartis 2013-07-31
NCT00654160 Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer https://ClinicalTrials.gov/show/NCT00654160 Completed Mayo Clinic 2010-11-30
NCT00633295 Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor https://ClinicalTrials.gov/show/NCT00633295 Completed Novartis 2010-05-31
NCT00623831 A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen https://ClinicalTrials.gov/show/NCT00623831 Completed Ludwig Institute for Cancer Research 2012-05-31
NCT00618319 An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST) https://ClinicalTrials.gov/show/NCT00618319 Completed Biogen 2010-04-30
NCT00580281 Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors https://ClinicalTrials.gov/show/NCT00580281 Completed Memorial Sloan Kettering Cancer Center 2013-10-31
NCT00570635 A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib https://ClinicalTrials.gov/show/NCT00570635 Completed Exelixis 2009-05-31
NCT00568750 Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors https://ClinicalTrials.gov/show/NCT00568750 Completed Swiss Group for Clinical Cancer Research 2012-01-18
NCT00510354 Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate https://ClinicalTrials.gov/show/NCT00510354 Completed Novartis 2012-11-30
NCT00500188 Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST https://ClinicalTrials.gov/show/NCT00500188 Completed M.D. Anderson Cancer Center 2011-07-31
NCT00471328 Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib https://ClinicalTrials.gov/show/NCT00471328 Completed Novartis 2008-08-31
NCT00464620 Trial of Dasatinib in Advanced Sarcomas https://ClinicalTrials.gov/show/NCT00464620 Completed Sarcoma Alliance for Research through Collaboration 2016-12-31
NCT00457743 A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST) https://ClinicalTrials.gov/show/NCT00457743 Completed Pfizer 2008-08-31
NCT00455559 Ph II Study of Perifosine Plus Gleevec for Patients With GIST https://ClinicalTrials.gov/show/NCT00455559 Completed AEterna Zentaris 2010-11-30
NCT00441155 Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib https://ClinicalTrials.gov/show/NCT00441155 Completed Novartis 2011-01-31
NCT00428220 A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. https://ClinicalTrials.gov/show/NCT00428220 Completed Pfizer 2014-08-31
NCT01039519 A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) https://ClinicalTrials.gov/show/NCT01039519 Completed Synta Pharmaceuticals Corp. 2011-12-31
NCT00385203 The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST). https://ClinicalTrials.gov/show/NCT00385203 Completed AstraZeneca 2008-06-30
NCT00367861 Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance https://ClinicalTrials.gov/show/NCT00367861 Completed Centre Leon Berard 2012-04-30
NCT00359333 Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Advanced/Metastatic Malignant GIST https://ClinicalTrials.gov/show/NCT00359333 Completed National Health Research Institutes, Taiwan 2010-04-30
NCT00293124 Open-label Trial of GlivecWith Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumors https://ClinicalTrials.gov/show/NCT00293124 Completed Central European Cooperative Oncology Group 2006-07-31
NCT00278876 Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation https://ClinicalTrials.gov/show/NCT00278876 Completed Asan Medical Center 2007-08-31
NCT00276302 Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS) https://ClinicalTrials.gov/show/NCT00276302 Completed Infinity Pharmaceuticals, Inc. 2010-11-30
NCT00265798 Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate https://ClinicalTrials.gov/show/NCT00265798 Active, not recruiting National Cancer Institute (NCI) 2010-02-11
NCT00254267 Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal Tumors https://ClinicalTrials.gov/show/NCT00254267 Completed Amgen 2007-02-28
NCT00237185 A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene https://ClinicalTrials.gov/show/NCT00237185 Completed Novartis 2013-06-30
NCT00237172 Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study) https://ClinicalTrials.gov/show/NCT00237172 Completed Novartis 2005-07-31
NCT00171977 Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) https://ClinicalTrials.gov/show/NCT00171977 Completed Novartis 2009-04-30
NCT00137449 Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor https://ClinicalTrials.gov/show/NCT00137449 Completed Pfizer 2008-04-30
NCT00135005 Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST) https://ClinicalTrials.gov/show/NCT00135005 Completed Novartis 2006-11-30
NCT00117299 PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib https://ClinicalTrials.gov/show/NCT00117299 Completed University of Helsinki 2007-09-30
NCT00116935 Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) https://ClinicalTrials.gov/show/NCT00116935 Completed Scandinavian Sarcoma Group 2010-12-31
NCT00112632 Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor https://ClinicalTrials.gov/show/NCT00112632 Completed Technische Universität München NA
NCT00112463 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma https://ClinicalTrials.gov/show/NCT00112463 Completed National Cancer Institute (NCI) 2008-10-23
NCT00103168 Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor https://ClinicalTrials.gov/show/NCT00103168 Completed European Organisation for Research and Treatment of Cancer - EORTC 2008-10-31
NCT00098579 Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT00098579 Completed National Cancer Institute (NCI) 2011-07-31
NCT00089960 Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs) https://ClinicalTrials.gov/show/NCT00089960 Completed Amgen 2006-06-30
NCT00087074 CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor https://ClinicalTrials.gov/show/NCT00087074 Completed National Cancer Institute (NCI) 2005-12-31
NCT00003939 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma https://ClinicalTrials.gov/show/NCT00003939 Completed European Organisation for Research and Treatment of Cancer - EORTC 2000-11-30
NCT00005874 Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas https://ClinicalTrials.gov/show/NCT00005874 Completed National Cancer Institute (NCI) NA
NCT00005862 SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas https://ClinicalTrials.gov/show/NCT00005862 Completed National Cancer Institute (NCI) 2004-07-31
NCT00075218 A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST) https://ClinicalTrials.gov/show/NCT00075218 Completed Pfizer 2008-05-31
NCT00069940 Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor https://ClinicalTrials.gov/show/NCT00069940 Completed Dana-Farber Cancer Institute 2006-08-31
NCT00004911 Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction https://ClinicalTrials.gov/show/NCT00004911 Completed Northwestern University 2003-02-28
NCT00004910 Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction https://ClinicalTrials.gov/show/NCT00004910 Completed Northwestern University 2003-02-28
NCT00004895 Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT00004895 Completed Northwestern University 2002-10-31
NCT00030667 Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood https://ClinicalTrials.gov/show/NCT00030667 Completed National Cancer Institute (NCI) 2005-12-31
NCT00041249 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma https://ClinicalTrials.gov/show/NCT00041249 Completed European Organisation for Research and Treatment of Cancer - EORTC 2004-01-31
NCT00041197 Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery https://ClinicalTrials.gov/show/NCT00041197 Completed National Cancer Institute (NCI) 2007-04-30
NCT00031681 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) https://ClinicalTrials.gov/show/NCT00031681 Completed National Cancer Institute (NCI) 2011-01-31
NCT00028002 Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor https://ClinicalTrials.gov/show/NCT00028002 Completed National Cancer Institute (NCI) 2009-01-28
NCT00025415 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00025415 Completed National Cancer Institute (NCI) 2005-01-31
NCT00025246 Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery https://ClinicalTrials.gov/show/NCT00025246 Completed National Cancer Institute (NCI) 2007-11-30
NCT00005597 S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors https://ClinicalTrials.gov/show/NCT00005597 Completed Southwest Oncology Group 2005-10-31
NCT00005049 Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer https://ClinicalTrials.gov/show/NCT00005049 Completed NYU Langone Health 2006-11-30
NCT00006357 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma https://ClinicalTrials.gov/show/NCT00006357 Completed European Organisation for Research and Treatment of Cancer - EORTC 2001-04-30
NCT00397384 Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer https://ClinicalTrials.gov/show/NCT00397384 Completed National Cancer Institute (NCI) 2013-06-30

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03722056 Laparoscopic Management of Gastrointestinal Stromal Tumor of Stomach https://ClinicalTrials.gov/show/NCT03722056 Completed GEM Hospital & Research Center 2015-07-31
NCT03092128 A Retrospective Pharmacokinetics and Pharmacogenomics Research of Imatinib in Gastrointestinal Stromal Tumor Treatment https://ClinicalTrials.gov/show/NCT03092128 Recruiting Sun Yat-sen University 2019-06-30
NCT02877368 Sarcopenia in Patients With Gastrointestinal Stromal Tumours https://ClinicalTrials.gov/show/NCT02877368 Completed CHU de Reims 2014-10-31
NCT02734823 Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor https://ClinicalTrials.gov/show/NCT02734823 Recruiting University of Southern California 2020-03-01
NCT02662478 Laparoscopic Resection of Large Gastric Stromal Tumors https://ClinicalTrials.gov/show/NCT02662478 Completed Medical Park Gaziantep Hospital 2016-01-31
NCT02331914 GIST: Assessment of Tumor Mutations and TKI Plasma Exposure https://ClinicalTrials.gov/show/NCT02331914 Recruiting University Medical Center Groningen 2020-09-30
NCT02171286 The Oncopanel Pilot (TOP) Study https://ClinicalTrials.gov/show/NCT02171286 Completed British Columbia Cancer Agency 2017-03-31
NCT01276483 Treatment Response Evaluation in Gastrointestinal Stromal Tumor (GIST) Patients https://ClinicalTrials.gov/show/NCT01276483 Completed Oslo University Hospital 2017-06-30
NCT01933958 Regorafenib Post-marketing Surveillance in Japan https://ClinicalTrials.gov/show/NCT01933958 Active, not recruiting Bayer 2020-11-30
NCT01865565 Surgery for Locally Unresectable Advanced GISTs Without Metastasis After Imatinib Therapy https://ClinicalTrials.gov/show/NCT01865565 Completed Chang Gung Memorial Hospital 2016-12-31
NCT01416714 Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy https://ClinicalTrials.gov/show/NCT01416714 Recruiting University of Chicago 2025-01-31
NCT04343456 Salvage Surgery for Patients With Metastatic GIST With Rego https://ClinicalTrials.gov/show/NCT04343456 Completed Chang Gung Memorial Hospital 2019-12-31
NCT04256226 Clinical Outcome of Female Non-gastric Gastrointestinal Stromal Tumor https://ClinicalTrials.gov/show/NCT04256226 Completed Far Eastern Memorial Hospital 2020-03-31
NCT04143048 A Study on Non-invasive Early Diagnosis of Gastrointestinal Stromal Tumors and Differentiation of Benign and Malignant Nodules https://ClinicalTrials.gov/show/NCT04143048 Recruiting The First Affiliated Hospital with Nanjing Medical University 2020-05-31
NCT03963544 Patterns of Care and Outcomes of Patients With METAstatic Gastrointestinal Stromal Tumors (METAGIST) https://ClinicalTrials.gov/show/NCT03963544 Recruiting Institut Bergonié 2020-09-30
NCT03716089 Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site https://ClinicalTrials.gov/show/NCT03716089 Enrolling by invitation Fujian Medical University 2021-04-01
NCT01265979 WB-DWI for Early Prediction of Therapy Response in Patients With Advanced Metastatic GIST Treated With Regorafenib https://ClinicalTrials.gov/show/NCT01265979 Completed Universitaire Ziekenhuizen Leuven 2011-09-30
NCT01178307 Symptom Inventory for Gastrointestinal Stromal Tumors https://ClinicalTrials.gov/show/NCT01178307 Active, not recruiting M.D. Anderson Cancer Center 2020-07-31
NCT01135849 B-Receptor Signaling in Cardiomyopathy https://ClinicalTrials.gov/show/NCT01135849 Completed Stanford University 2010-10-31
NCT01048281 Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma https://ClinicalTrials.gov/show/NCT01048281 Recruiting Stanford University 2099-01-31
NCT00976612 Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK https://ClinicalTrials.gov/show/NCT00976612 Completed Asan Medical Center 2011-08-31
NCT00954655 Study of Tumor Samples in Patients Undergoing Treatment for Gastrointestinal Stromal Tumors on Clinical Trial ACOSOG-Z9001 https://ClinicalTrials.gov/show/NCT00954655 Completed Alliance for Clinical Trials in Oncology 2013-04-30
NCT00877045 Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting https://ClinicalTrials.gov/show/NCT00877045 Completed SCRI Development Innovations, LLC 2009-01-31
NCT00718211 A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore https://ClinicalTrials.gov/show/NCT00718211 Completed National University Hospital, Singapore 2013-09-30
NCT00716820 Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan). https://ClinicalTrials.gov/show/NCT00716820 Completed Pfizer 2015-10-31
NCT00700258 Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] https://ClinicalTrials.gov/show/NCT00700258 Recruiting Pfizer 2023-12-01
NCT00564265 Current Management of Gastrointestinal Stromal Tumors (GIST) in the Region of Coquimbo https://ClinicalTrials.gov/show/NCT00564265 Completed Cirujanos la Serena 2008-06-30
NCT00507273 Gastrointestinal Stromal Tumors (GIST) Registry https://ClinicalTrials.gov/show/NCT00507273 Completed M.D. Anderson Cancer Center 2010-12-31
NCT00444795 Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene https://ClinicalTrials.gov/show/NCT00444795 Completed Pfizer 2015-03-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT04181970 Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK https://ClinicalTrials.gov/show/NCT04181970 Recruiting Grupo Espanol de Investigacion en Sarcomas 2022-01-30